Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1990-5-7
|
pubmed:abstractText |
Thirty-two assessable patients with metastatic urothelial tumors refractory to standard chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were treated with escalated doses of MVAC plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Results of this phase I trial revealed that escalated MVAC (30 mg of methotrexate/m2, 4 mg of vinblastine/m2, 60 mg of doxorubicin/m2, and 100 mg of cisplatin/m2) can be tolerated by heavily pretreated patients. The side effects of rhGM-CSF are dose- and schedule-dependent. The maximum tolerated dose is 250 micrograms/m2 per day as a single dose administered subcutaneously (SC) for 10 consecutive days. This dose is well tolerated in outpatients, resulting in only modest fever and few side effects. The same dose delivered as a continuous infusion or a higher dose delivered either as a continuous infusion or SC caused significant side effects. For phase II trials, the starting dose of rhGM-CSF when combined with escalated MVAC is 120 micrograms/m2 per day SC for 10 consecutive days. forty percent of the treated patients responded, seven (23%) with complete remission and five (17%) with partial remission. This response rate is higher than anticipated from such a modest dosage escalation in chemotherapy-refractory patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Colony-Stimulating Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Substances,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0027-8874
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
18
|
pubmed:volume |
82
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
667-72
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2181151-Agranulocytosis,
pubmed-meshheading:2181151-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2181151-Bone Marrow,
pubmed-meshheading:2181151-Cisplatin,
pubmed-meshheading:2181151-Colony-Stimulating Factors,
pubmed-meshheading:2181151-Doxorubicin,
pubmed-meshheading:2181151-Female,
pubmed-meshheading:2181151-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:2181151-Growth Substances,
pubmed-meshheading:2181151-Humans,
pubmed-meshheading:2181151-Male,
pubmed-meshheading:2181151-Methotrexate,
pubmed-meshheading:2181151-Recombinant Proteins,
pubmed-meshheading:2181151-Urinary Bladder Neoplasms,
pubmed-meshheading:2181151-Vinblastine
|
pubmed:year |
1990
|
pubmed:articleTitle |
Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
|
pubmed:affiliation |
Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
|
pubmed:publicationType |
Journal Article
|